Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924450 | 0.89 | PTGS2 (0.49) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL9320686 | 0.87 | PTGS2 (0.50) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL20312883 | 0.83 | PTGS2 (0.40) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL12011032 | 0.81 | PTGS2 (0.57) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL13761288 | 0.81 | PTGS2 (0.44) | PTGS2PTGS1RPS6KA3ACHEBACE1 | |
| SCHEMBL17359262 | 0.81 | RPS6KA3 (0.46) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL24159755 | 0.80 | PTGS2 (0.34) | PTGS2PTGS1 | |
| SCHEMBL13301268 | 0.80 | PTGS2 (0.53) | PTGS2PTGS1RPS6KA3ACHEPDE3B | |
| SCHEMBL25217680 | 0.80 | KCNQ3 (0.33) | PTGS2PTGS1 | |
| SCHEMBL172423 | 0.79 | ACHE (0.48) | PTGS2PTGS1RPS6KA3ACHEPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952207-B2 | Copper-catalyzed C—H bond arylation | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076266-A1 | COPPER-CATALYZED C-H BOND ARYLATION | AOC2, AOC3, DBH | PTGS2 2323/4885PTGS1 2445/4885RPS6KA3 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.